ArticleFrontiers in oncology2026
Transcription factor SOX4 promotes proliferation, invasion and lymphatic metastasis of laryngeal squamous cell carcinoma via PTBP2 activation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Laryngeal squamous cell carcinoma (LSCC) is a common malignant tumor in otorhinolaryngology, with a high incidence rate and a tendency of lymph node metastasis. This study aims to systematically evaluate the expression of the transcription factor SOX4 in LSCC and its clinical relevance, clarify its impact on the biological behavior of tumors and potential molecular mechanisms, and provide a theoretical basis for diagnosis and treatment. Method: Bioinformatics analysis was conducted based on the GEO dataset (GSE201777) to evaluate the expression of SOX4 and its clinical relevance; The expression of SOX4 in LSCC clinical tissues and cell lines was verified by qRT-PCR. SOX4 knockdown and overexpression cell models were constructed. Proliferation was evaluated by MTS and colony formation assays, migration and invasion were evaluated by scratch and Transwell assays, and apoptosis was detected by flow cytometry and TUNEL. The downstream effector molecules of SOX4 were screened by transcriptome sequencing and verified by functional recovery experiments. The association between SOX4 and tumor immune infiltration as well as drug sensitivity was explored by combining bioinformatics analysis. Ultimately, the effects of SOX4 on tumor growth and lymph node metastasis Result: Bioinformatics and experimental data consistently showed that SOX4 was upregulated in LSCC and positively correlated with disease progression and lymph node metastasis. Conclusion: SOX4 promotes the growth and lymph node metastasis of LSCC by regulating PTBP2. The SOX4-PTBP2 axis may become a potential diagnostic and therapeutic target for LSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.